We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+6.39%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.88B
AUM Growth
-$490M
Cap. Flow
-$546M
Cap. Flow %
-9.3%
Top 10 Hldgs %
73.83%
Holding
50
New
3
Increased
19
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$140M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$127M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$76.3M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$53.4M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$41.8M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$688M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$144M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$120M
4
TRIL
Trillium Therapeutics Inc.
TRIL
+$100M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$36.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DSGN icon
26
Design Therapeutics
DSGN
$862M
$35M 0.6%
1,636,100
+167,782
+11% +$2.88M
KYMR icon
27
Kymera Therapeutics
KYMR
$8.75B
$34.9M 0.59%
550,000
+94,250
+21% +$5.49M
CBAY
28
DELISTED
Cymabay Therapeutics
CBAY
$34.8M 0.59%
10,300,000
– –
PMVP icon
29
PMV Pharmaceuticals
PMVP
$62.9M
$33.8M 0.58%
1,465,000
-1,460,000
-50% -$35.3M
KRYS icon
30
Krystal Biotech
KRYS
$9.55B
$33.2M 0.57%
+475,000
New +$27.6M
RNAM
31
DELISTED
Avidity Biosciences
RNAM
$29.2M 0.5%
1,230,000
+80,000
+7% +$1.91M
AMRN
32
Amarin Corp
AMRN
$301M
$20.2M 0.34%
300,000
– –
NUVL
33
DELISTED
Nuvalent
NUVL
$18.4M 0.31%
1,102,671
-155,000
-12% -$3.45M
TNGX icon
34
Tango Therapeutics
TNGX
$4.72B
$17M 0.29%
1,550,000
– –
DICE
35
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$14.2M 0.24%
562,500
-237,500
-30% -$6.96M
AVDL
36
DELISTED
Avadel Pharmaceuticals
AVDL
$13.5M 0.23%
1,670,000
-605,000
-27% -$5.53M
ADVM
37
DELISTED
Adverum Biotechnologies
ADVM
$12.2M 0.21%
695,000
– –
IOBT
38
DELISTED
IO Biotech
IOBT
$10.2M 0.17%
+2,055,883
New +$19.9M
GNCA
39
DELISTED
Genocea Biosciences, Inc.
GNCA
$5.9M 0.1%
5,084,184
– –
FENC icon
40
Fennec Pharmaceuticals
FENC
$377M
$5.28M 0.09%
1,200,000
-470,000
-28% -$3.5M
SRPT icon
41
CALL
Sarepta Therapeutics
SRPT
$1.77B
$2.91M 0.05%
300,000
+100,000
+50% +$8.55M
APLS
42
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-1,515,000
Closed -$1.26M
BIIB icon
43
Biogen
BIIB
$30.5B
– –
-84,000
Closed -$23.8M
IOVA icon
44
CALL
Iovance Biotherapeutics
IOVA
$2.77B
– –
-650,000
Closed -$1.54M
MRUS
45
DELISTED
Merus
MRUS
– –
-450,000
Closed -$9.9M
VRTX icon
46
Vertex Pharmaceuticals
VRTX
$123B
– –
-664,000
Closed -$120M
DCPH
47
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-1,068,000
Closed -$36.3M
XLRN
48
CALL
DELISTED
Acceleron Pharma
XLRN
– –
-476,100
Closed -$32K
XLRN
49
DELISTED
Acceleron Pharma
XLRN
– –
-4,000,000
Closed -$688M
TRIL
50
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-5,700,000
Closed -$100M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Avoro Capital Advisors held 50 positions worth $5.88B, down 7.7% from $6.37B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Avoro Capital Advisors withdrew a net $546M in Q4 2021, closing 9 positions and reducing 6 holdings. Its most notable exit was Acceleron Pharma, an estimated $688M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in State Street SPDR S&P Biotech ETF worth $118M.

  • Avoro Capital Advisors's largest Q4 2021 buy was State Street SPDR S&P Biotech ETF: 1,050,000 shares worth $118M.
  • Avoro Capital Advisors added most to Apellis Pharmaceuticals in Q4 2021, an estimated $140M increase.
  • Avoro Capital Advisors's biggest Q4 2021 reduction was Arena Pharmaceuticals Inc, cutting an estimated $144M.
  • Avoro Capital Advisors fully exited Acceleron Pharma in Q4 2021, selling an estimated $688M.
  • Avoro Capital Advisors's ten largest holdings make up 74% of its $5.88B portfolio in Q4 2021.
  • Avoro Capital Advisors opened 3 new positions and closed 9 in Q4 2021.
  • Avoro Capital Advisors's portfolio value fell 7.7% quarter-over-quarter to $5.88B.

Based on Avoro Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.